Reimagining Medicine slide image

Reimagining Medicine

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Oncology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 65 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation